Basic and clinical study on cefluprenam

DOI 5 References

Bibliographic Information

Other Title
  • 注射用セフェロスポリン系抗生物質cefluprenamの基礎的・臨床的研究

Search this article

Description

We performed the basic and clinical study on cefluprenam (CFLP), a new parenteral cephalosporin.The in vitro antibacterial activity of CFLP was compared with those of cefozopran (CZOP) and ceftazidime (CAZ) against recent clinical isolates.CFLP showed a broad antibacterial spectrum against gram-positive and gram-negative bacteria.Against Staphylococcus aureus, Enterococcus faecalis, and members of the family Enterobacteriaceae, except for Serratia marcescens and Proteus vulgaris, CFLP was 2-to 4-fold more active than CZOP The activity of CFLP against Pseudomonas aeruginosa was almost the same as that of CZOP and was about 2-fold higher than that of CAZ.The in vitro synergistic activities of CFLP in combination with cefazolin (CEZ), cefotiam (CTM), and fosfomycin were examined against methicillinresistant strains of S.aureus (MRSA). Combinations of CFLP plus CEZ and CFLP plus CTM demonstrated synergy against 70 and 80 % of the MRSA strains, respectively.CFLP was administered to 27 patients with various infections, consisted of 3 with sepsis, 1 with sepsis suspected, 8 with pneumonia, 1 with lung abscess, 3 with bronchopneumonia, 4 with acute bronchitis, 5 with chronic bronchitis, 1 with bronchiectasis and 1 with pyelonephnitis. The overall efficacy rate was 95.5%(21/22).Skin rash was observed in 1 patient. Eosinophilia and elevations in S-GPT were observed in three patients, respectively.

Journal

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top